Organon (OGN) announced that Vtama cream, 1%, was granted a recommendation by the American Academy of Dermatology in their 2025 focused guideline update for the management of adults with moderate to severe atopic dermatitis. The recommendation underscores Vtama cream as an effective, steroid-free option for daily disease management, with no label warnings or precautions, no contraindications, and no restrictions on duration of use or percentage of body surface area affected.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN:
- Morning Movers: Tesla higher following Q2 delivery figures
- Organon ELENA trial misses primary endpoint, to discontinue OG-6219 program
- OGN Lawsuit Alert! Class Action Lawsuit Against Organon & Co.
- Organon Concludes Annual Meeting with Key Decisions
- Organon Receives FDA Interchangeability for HADLIMA